Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Cardiac Autonomic Dysfunction in Lymphoma Survivors
NCT03137537Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivabradine in Cardiac autonomic dysfunction (CAN), sponsored by Dana-Farber Cancer Institute. Started Feb 2018; status: terminated.
02
Drugs
ivabradine
03
Conditions
Cardiac autonomic dysfunction (CAN)
Beyond the preview
Go deeper on NCT03137537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137537.